No. |
DrugBank |
Drug (Description in trials) [Number of descriptions] |
KEGG DRUG * | KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 | Afamelanotide | [1] Afamelanotide; | D10511 |
- |
- |
[2] 49, 254 |
2 | Ascorbic acid | [4] 2l polyethylene glycol/ascorbic acid; Ascorbic acid; Ascorbic acid (vitamin c); Ascorbic acid vit c; | D00018 |
- |
- |
[13] 10, 13, 49, 62, 86, 96, 97, 192, 206, 211, 212, 254, 284 |
3 | Chlorpromazine | [2] Chlorpromazine; Chlorpromazine hydrochloride; | D00270 D00789 D03274 D04034 |
[13] ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD2, HRH1, HTR2A, HTR2B, HTR2C |
[20] Alcoholism, Calcium signaling pathway, Cholinergic synapse, Cocaine addiction, Dopaminergic synapse, Gap junction, Gastric acid secretion, Inflammatory mediator regulation of TRP channels, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Parkinson disease, Rap1 signaling pathway, Regulation of actin cytoskeleton, Salivary secretion, Serotonergic synapse, Taste transduction, cAMP signaling pathway, cGMP-PKG signaling pathway |
[1] 254 |
4 | Cholestyramine | [1] Cholestyramine; | - |
- |
- |
[5] 13, 79, 93, 254, 297 |
5 | Colestipol | [1] Colestipol; | D02113 D07771 |
- |
- |
[1] 254 |
6 | Cyanocobalamin | - | D00166 D03615 D03616 D03617 |
- |
- |
[12] 6, 13, 49, 62, 86, 96, 97, 201, 229, 254, 284, 299 |
7 | Deferasirox | [1] Deferasirox; | D03669 |
- |
- |
[3] 254, 284, 286 |
8 | Docusate | - | D00305 |
- |
- |
[7] 13, 62, 86, 96, 97, 254, 284 |
9 | Folic acid | [5] Folic acid; Folic acid or folate; Folic acid, vitamin b6, vitamin b12; Methotrexate and folic acid; Rituximab, mtx, folic acid; | D00070 |
- |
- |
[11] 6, 13, 46, 49, 62, 84, 86, 96, 97, 254, 284 |
10 | Givosiran | [2] Givosiran; Givosiran (aln-as1); | - |
- |
- |
[1] 254 |
11 | Hemin | [2] Hemin; Hemin for injection; | D10003 |
[2] ALAS1, ALAS2 |
[3] Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin and chlorophyll metabolism |
[1] 254 |
12 | Hydroxychloroquine | [16] Hydroxychloroquine; Hydroxychloroquine (z0188); Hydroxychloroquine + prednisone; Hydroxychloroquine high; Hydroxychloroquine higher dose; Hydroxychloroquine lower dose; Hydroxychloroquine or chloroquine; Hydroxychloroquine reduced; Hydroxychloroquine sulfate; Hydroxychloroquine sulphate; Leflunomide-sulfasalazine-hydroxychloroquine; Methotrexate + salazopyrine + hydroxychloroquine administration; Methotrexate-sulfasalazine-hydroxychloroquine; Sirolimus and hydroxychloroquine; Sulphasalazine + hydroxychloroquine or prednisolone; Versus hydroxychloroquine; | D08050 |
- |
- |
[18] 13, 41, 46, 48, 49, 53, 56, 66, 84, 89, 90, 96, 222, 234, 254, 271, 298, 299 |
13 | Iron | [14] Injection of iron; Iron; Iron chelating agents; Iron dextran; Iron oxide; Iron sucrose; Iron sulphate; Iron sulphate 200mg coated tablets; Iron supplement; Iron supplement 300-600 mg/day; Iron(iii)- hydroxide dextran complex; Oral iron; Ultra small particles of iron oxide (uspio); Ultrasmall particles of iron oxide; | - |
- |
- |
[7] 13, 62, 86, 96, 97, 254, 284 |
14 | Isoniazid | [1] Isoniazid; | D00346 D01501 D02002 |
- |
- |
[1] 254 |
15 | L-Cysteine | - | D00026 D02326 |
- |
- |
[9] 6, 13, 19, 84, 85, 88, 90, 254, 296 |
16 | Ledipasvir | [2] Ledipasvir; Ledipasvir/sofosbuvir; | D10442 |
- |
- |
[2] 19, 254 |
17 | Luteinizing hormone | [2] Luteinizing hormone; Luteinizing hormone-releasing factor; | - |
- |
- |
[1] 254 |
18 | Porphobilinogen | [2] Porphobilinogen; Recombinant human porphobilinogen deaminase (porphozym); | - |
- |
- |
[1] 254 |
19 | Sofosbuvir | [2] Ledipasvir/sofosbuvir; Sofosbuvir; | D10366 |
- |
- |
[2] 19, 254 |
20 | Stannsoporfin | - | D05922 |
[2] HMOX1, HMOX2 |
[9] Ferroptosis, Fluid shear stress and atherosclerosis, HIF-1 signaling pathway, Hepatocellular carcinoma, Metabolic pathways, MicroRNAs in cancer, Mineral absorption, Pathways in cancer, Porphyrin and chlorophyll metabolism |
[1] 254 |